MedPath

Bilastine

Generic Name
Bilastine
Brand Names
Blexten
Drug Type
Small Molecule
Chemical Formula
C28H37N3O3
CAS Number
202189-78-4
Unique Ingredient Identifier
PA1123N395
Background

Bilastine is a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action.

Indication

For symptomatic relief of nasal and non-nasal symptoms of seasonal rhinitis in patients 12 years of age and older and for symptomatic relief in chronic spontaneous urticaria in patients 18 years of age and older .

Associated Conditions
Chronic Spontaneous Urticaria, Seasonal Allergic Rhinitis
Clinical Trials
Related News

Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria

Phase 3
Completed
Conditions
Urticaria
Interventions
Drug: Placebo
First Posted Date
2007-01-11
Last Posted Date
2012-04-05
Lead Sponsor
Faes Farma, S.A.
Target Recruit Count
522
Registration Number
NCT00421109
Locations
🇧🇪

Centre nº 204, Gent, Belgium

🇦🇷

Centre nº 107, Buenos Aires, Argentina

🇵🇱

Centre nº 507, Krakow, Poland

and more 47 locations

A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber

Phase 2
Completed
Conditions
Seasonal Allergic Rhinitis
Interventions
Drug: Placebo
First Posted Date
2007-01-09
Last Posted Date
2012-04-05
Lead Sponsor
Faes Farma, S.A.
Target Recruit Count
75
Registration Number
NCT00420082
Locations
🇦🇹

Allergy Center Vienna West, Vienna, Austria

A Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic (ECG) Effects of Bilastine

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2007-01-09
Last Posted Date
2012-04-05
Lead Sponsor
Faes Farma, S.A.
Target Recruit Count
30
Registration Number
NCT00419783
Locations
🇺🇸

MDS Pharma Services, Phoenix, Arizona, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy